Thymmune Therapeutics
Biotech firm developing thymic cell therapies to restore immune function using machine learning
26 employees · est. 2019 · Cambridge, United States
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | DeepLife | Thymmune Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2019 |
| Headquarters | ||
| Headquarters | Paris, France | Cambridge, United States |
| Employees | ||
| Employees | 31 | 26 |
| Industry | ||
| Industry | AI, Biotechnology, Machine Learning | Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series A | Seed |
| Total Funding | ||
| Total Funding | $16.00M | $44.30M |
| Funding Rounds | ||
| Funding Rounds | 3 | 3 |
| Services | ||
| Services | Development of digital twins for cells, Drug discovery solutions, Multi-omics data analysis, AI and systems engineering for biotech applications | Development of thymic cell engineering platform, Mass production of iPSC-derived thymic cells, Research and development of therapies for immune disorders, Preclinical studies of thymic cell therapy, Therapeutic development for healthy immune aging |
| Target Customers | ||
| Target Customers | Pharmaceutical companies, Biotech researchers, Health institutions, Investors interested in biotech innovations, Scientific collaborators | Patients with immune-mediated diseases, Individuals with immunodeficiencies, Patients experiencing age-related immune decline, Healthcare professionals seeking innovative treatments |
| Taxonomy | ||
| Taxonomy | Digital Twin, Cell Engineering, SaaS Platform, Multi-omics Sequencing, Deep Learning Algorithms, In Silico Simulations, Pharmaceutical Target Identification, Molecular Triggers, System Biology, Translational Research, Biotech Collaboration, Cell Atlases, Deep Learning-Based Tools, Drug Discovery | Thymic Cell Therapies, IPSC Manufacturing, Immunotherapy, Immune Restoration, Aging, Disease Treatment, Immunodeficiencies, Transplant Therapeutics, Autoimmune Diseases, Cell Engineering, Off-the-shelf Therapies, Therapeutic Pipeline, Biotech Innovation |
| Website | ||
| Website | deeplife.co | thymmune.com |
About DeepLife
DeepLife, an innovative startup founded in 2019, is making significant strides in biotechnology by developing the first SaaS platform for creating a Digital Twin of cells. They leverage advanced AI and machine learning to transform cell engineering by simulating cell behavior in silico, aiming to co...
About Thymmune Therapeutics
Thymmune Therapeutics, a Cambridge, MA-based biotech firm, is pioneering in the realm of thymic cell therapies with an innovative use of machine learning to restore immune function. Founded in 2019, the company focuses on developing a unique platform that utilizes iPSC-thymic cell manufacturing to p...
We will tell you when either one moves
BounceWatch watches DeepLife and Thymmune Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at DeepLife and Thymmune Therapeutics — by email.
Frequently Asked Questions
Compare DeepLife with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at DeepLife on 15 Jun 2026, and Thymmune Therapeutics on 4 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
